Invasive pneumococcal infections and the impact of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13). 2021 Report.

Key Points

  • In 2021, the overall incidence rate of invasive pneumococcal infections decreased, but the decline was less pronounced than in the previous year and varied by age group.

  • The incidence rate was highest and rising again among children under 2 years of age, though levels remained below those of 2019, before the onset of the COVID-19 pandemic.

  • Among those aged 65 and older, incidence rates remain among the highest, with a more moderate decrease compared to the previous year.

  • The majority of infections were caused by serotypes not included in the PCV13 vaccine (notably serotype 8 in adults and serotype 24F in children), as well as by serotype 3 (included in PCV13) in adults.

In relation to

Our latest news

news

Launch of the “Heating, Health, Buildings, and Urban Planning” Network:...

news

2026 “Sexual Behavior” Survey (ERAS) for men who have sex with men

news

Hervé Maisonneuve has been appointed scientific integrity officer for a...